- Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPILLON subgroup analysisZhou, C.; Tang, K.; Liu, B.; Kim, S-W.; Kitazono, S.; Ono, A.; Thiagarajan, M.; Hung, J-Y.; Boyer, M.; Xie, J.; Bhattacharya, A.; Baig, M.; Agrawal, T.; Knoblauch, R. E.; Cho, B. C.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- Efficacy of various types of chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 in-frame insertions.Tang, Haibo; Li, Xiaoning; Cai, Jianhong; Wu, Xiaomin; Zheng, Yating; Huang, MengliVirtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2021-06-04 To 2021-06-08.
- Brief Report: Immunochemotherapy in Five Patients with EGFR Exon 20 Insertion Advanced Lung AdenocarcinomaPeng, K.; Wang, H.; Gao, Y.; Li, X.; Gao, Q.; Zhang, S.; Yang, J.
会议论文
Efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer harboring ERBB2 exon 20 insertions and non-ERBB2 exon 20 insertions
13阅读
